A Case Report of Lithium-Induced Tardive Dyskinesia

Chutimon Boonrod; Keerati Pattanaseri; Juthawadee Lortrakul

doi:10.31584/jhsmr.20251138

Authors

Chutimon Boonrod Department of Psychiatry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Keerati Pattanaseri Department of Psychiatry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Juthawadee Lortrakul Department of Psychiatry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

DOI:

https://doi.org/10.31584/jhsmr.20251138

Keywords:

adverse effects, bipolar disorder, lithium, tardive dyskinesia

Abstract

Our case involves an elderly patient with bipolar disorder with a history of long-term low-dose lithium monotherapy (600 mg/day) who subsequently developed tardive dyskinesia as an adverse drug reaction. Generally, tardive dyskinesia is an iatrogenic movement disorder resulting from the long-term use of dopamine-blocking agents. However, lithium, a mood stabilizer with a mechanism of action that is not completely understood, has also been identified in some studies for its potential impact on dopamine synthesis and transmission. While common adverse effects of lithium include nausea, vomiting, and fine tremors, it rarely causes movement disorders. Limited reports exist regarding tardive dyskinesia associated with lithium usage. Following normal laboratory investigations, lithium was discontinued and diazepam was prescribed instead. Subsequent follow-up visits showed an improvement in symptoms.

References

Boland R, Verduin M, Ruiz P. Kaplan & Sadock’s synopsis of psychiatry. 12th edition. Philadelphia: Wolters Kluwer; 2022.

Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov 2013;3.

Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 2014;11:166-76.

Witter DP, Holbert RC, Suryadevara U. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opin Pharmacother 2017. doi: 10.1080/14656566.2017.1323874.

Corbella, B, Vieta E. Molecular targets of lithium action. Acta Neuropsychiatr 2003;15:316-40. doi: 10.1046/j.1601-5215.2003.00049.x.

Lennox R, Mangi XX. Lithium. In: Schatzberg A, Nemeroff C, Psychopharmacology. Washington: The American Psychiatry Press; 1998:379–427.

Swerdlow NR, Lee D, Koob GF, Vaccarino FJ. Effects of chronic dietary lithium on behavioral indices of dopamine denervation supersensitivity in the rat. J Pharmacol Exp Ther 1985;235:324–9.

Chakrabarti S, Chand PK. Lithium-induced tardive dystonia. Neurol India 2002;50:473.

Aggarwal R, Garg D, Dhamija RK. Lithium-Induced Lingual Dystonia. Ann Indian Acad Neurol 2020;23:383-34. doi: 10.4103/aian.AIAN_369_19.

Meyer-Lindenberg A, Krausnick B. Tardive dyskinesia in a neuroleptic-naive patient with bipolar-I disorder: persistent exacerbation after lithium intoxication. Mov Disord 1997;12:1108–1109.

Dinan T, Kohen D. Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. Br J Psychiatry 1989;155:55-7. doi: 10.1192/bjp.155.1.55.

Fountoulakis KN, Tegos T, Kimiskidis V. Lithium monotherapy-induced tardive dyskinesia. J Affect Disord 2019;244:78–9.

Touma KTB, Scarff JR. Valbenazine and Deutetrabenazine for Tardive Dyskinesia. Innov Clin Neurosci 2018;15:13-6.

Ricciardi L, Pringsheim T, Barnes TRE, Martino D, Gardner D, Remington G, et al. Treatment Recommendations for Tardive Dyskinesia. Can J Psychiatry 2019;64:388-99. doi: 10.1177/0706743719828968.